Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2016

Planlagt Fastgjort Låst Flyttet Genmab
2.7k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #2538

    Så det er jo næsten et free ride de næste 5-8 år og så bare håbe, at en eller to andre kandidater kommer hele vejen eller godt på vej !!

    1 Reply Last reply
    0
    • dingleberryD Offline
      dingleberryD Offline
      dingleberry
      wrote on sidst redigeret af
      #2539

      absolut! Sukkeralf, har du styr på, hvilket organ i EMA, der står for den endelige markedsføringsgodkendelse? Jeg kan ikke lige finde den. Du postede på et tidspunkt et link til en ppt over godkendelsesprocessen...

      1 Reply Last reply
      0
      • dingleberryD Offline
        dingleberryD Offline
        dingleberry
        wrote on sidst redigeret af
        #2540

        var det den her - http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2009/10/WC500004235.pdf

        1 Reply Last reply
        0
        • dingleberryD Offline
          dingleberryD Offline
          dingleberry
          wrote on sidst redigeret af
          #2541

          GEN siger selv - The CHMP reviewed DARZALEX under the EMA's accelerated assessment program. A final decision by the European Commission is anticipated in 60 — 90 days.

          1 Reply Last reply
          0
          • dingleberryD Offline
            dingleberryD Offline
            dingleberry
            wrote on sidst redigeret af
            #2542

            så ifølge dem selv, kommer godkendelse tidligst ultimo maj, da udtalelsen var dateret 010416

            1 Reply Last reply
            0
            • dingleberryD Offline
              dingleberryD Offline
              dingleberry
              wrote on sidst redigeret af
              #2543

              ...men kommissionens pharmaceutiske kommitte er ikke ligefrem super opdateret - http://ec.europa.eu/health/documents/pharmaceutical-committee/index_en.htm

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #2544

                Ja det var det link jeg smed for noget tid siden !

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #2545

                  Tror vi skal regne med et par måneder fra CHMP anbefalingen

                  1 Reply Last reply
                  0
                  • dingleberryD Offline
                    dingleberryD Offline
                    dingleberry
                    wrote on sidst redigeret af
                    #2546

                    det ser dog ud til at COMP har sendt den videre i systemet

                    1 Reply Last reply
                    0
                    • F Offline
                      F Offline
                      FamaFrench
                      wrote on sidst redigeret af
                      #2547

                      Hvornår forventes der Dara salgstal fra Symphogen?

                      1 Reply Last reply
                      0
                      • M Offline
                        M Offline
                        MUFC_Oberanven
                        wrote on sidst redigeret af
                        #2548

                        Symphony Health data kommer typisk mellem den 20 og 25 I måneden

                        1 Reply Last reply
                        0
                        • M Offline
                          M Offline
                          mobbyduck1
                          wrote on sidst redigeret af
                          #2549

                          har vi fået tallen i denne måned??? jeg har ikke set dem!

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            mobbyduck1
                            wrote on sidst redigeret af
                            #2550

                            tallene

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #2551

                              Link Preview Image
                              Blodkræftmiddel sparker året i gang for Celgene

                              Det amerikanske biotekselskab Celgene er kommet fint fra start i 2016, særligt båret af dets flagskib, kræftmidlet Revlimid, og en af de nyere bestsellere. Til gengæld ser udsigterne for 2017 mørkere ud.

                              favicon

                              (medwatch.dk)

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #2552

                                Celgene skovler penge ind på Revlimid - et godt tegn på hvad Darzalex kan blive til med tiden

                                1 Reply Last reply
                                0
                                • dingleberryD Offline
                                  dingleberryD Offline
                                  dingleberry
                                  wrote on sidst redigeret af
                                  #2553

                                  sukkeralf,artiklen er lukket - kan du se, hvor stor omsætnigen er?

                                  1 Reply Last reply
                                  0
                                  • dingleberryD Offline
                                    dingleberryD Offline
                                    dingleberry
                                    wrote on sidst redigeret af
                                    #2554

                                    fandt den selv - •REVLIMID® sales for the first quarter increased 17 percent to $1,574 million. Growth was driven by increased market share in newly diagnosed multiple myeloma and increases in duration. U.S. sales of $997 million and international sales of $577 million increased 23 percent and 8 percent, respectively

                                    1 Reply Last reply
                                    0
                                    • M Offline
                                      M Offline
                                      MUFC_Oberanven
                                      wrote on sidst redigeret af
                                      #2555

                                      • Celgene Execs Say The Fundamentals For Revlimid And Pomalyst Are Both Exceptionally Strong - Conf Call

                                      1 Reply Last reply
                                      0
                                      • M Offline
                                        M Offline
                                        MUFC_Oberanven
                                        wrote on sidst redigeret af
                                        #2556

                                        • Celgene Execs Say 2020 Revlimid Forecast Is Conservative - Conf Call

                                        1 Reply Last reply
                                        0
                                        • M Offline
                                          M Offline
                                          MUFC_Oberanven
                                          wrote on sidst redigeret af
                                          #2557

                                          2017 net product sales expected to be: ◾ REVLIMID®: $7,000 million
                                          ◾ POMALYST®/IMNOVID®: $1,500 million

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger